{"schema_version":"secwatch.filing_event.v1","accession":"0001680367-22-000031","form_type":"8-K","ticker":"STTK","cik":"0001680367","company_name":"Shattuck Labs, Inc.","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.690508+00:00","generated_at":"2026-06-22T03:55:52.531243+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Shattuck Labs Q3 net loss $24.6M; cash $185.1M; SL-172154 trial enrollment complete","bullets":["Net loss of $24.6M ($0.58/share) vs $17.4M ($0.41/share) in Q3 2021, driven by higher R&D and G&A costs.","Cash and investments $185.1M as of Sep 30, 2022, down from $268.8M at Dec 31, 2021; cash runway into H2 2024.","Completed enrollment in Phase 1 monotherapy dose-escalation of SL-172154 in platinum-resistant ovarian cancer; final data expected midyear 2023.","First patient dosed in Phase 1B combination trial of SL-172154 with liposomal doxorubicin in ovarian cancer; initial data expected midyear 2023.","R&D expenses $18.9M (up 25% YoY); G&A $6.6M (up 53% YoY, including $1.4M litigation settlement)."],"urls":{"canonical":"https://secwatch.observer/filing/0001680367-22-000031","json":"https://secwatch.observer/filing/0001680367-22-000031.json","markdown":"https://secwatch.observer/filing/0001680367-22-000031.md","text":"https://secwatch.observer/filing/0001680367-22-000031.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680367/000168036722000031/0001680367-22-000031-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680367/000168036722000031/sttk-20221108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T03:55:52.531243+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"39eacbee807fe030f1f94d9fc230e3408d3def0e","claim":"Shattuck Labs, Inc. reported the quarter ended September 30, 2022 results: net income ($0.58) per basic and diluted share, EPS $0.58 per basic and diluted share.","evidence_excerpt":"Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today reported financial results for the quarter ended September 30, 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1680367/000168036722000031/0001680367-22-000031-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Net income","value":"($0.58) per basic and diluted share"},{"label":"EPS","value":"$0.58 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}